Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SLAM DRILLS MORE COPPER MINERALIZATION AT GOODWIN (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

Recent & Breaking News (GREY:ATBPF)

Phase 2B GI Safety Results For ATB-346 Published in British Journal of Pharmacology

Press Releases April 16, 2019

Phase 2B GI Safety Results For ATB-346 Published in British Journal of Pharmacology

Business Wire April 16, 2019

Antibe Therapeutics Announces Commencement of Phase 2B Dose-Ranging, Efficacy Study for Lead Drug, ATB-346

Business Wire March 29, 2019

Antibe Therapeutics Inc. Announces Closing of $5.75 Million Bought Deal Offering

Business Wire February 27, 2019

Antibe Therapeutics Recognized as a 2019 TSX Venture 50 Company

Business Wire February 22, 2019

Antibe Therapeutics Reports Q3 2019 Interim Financial and Operating Results

Business Wire February 15, 2019

IIROC Trading Resumption - ATE

Canada NewsWire February 4, 2019

Antibe Therapeutics Announces $5 Million Bought Deal Offering

Business Wire February 4, 2019

IIROC Trading Halt - ATE

Canada NewsWire February 4, 2019

Antibe Therapeutics Receives Approval to Initiate Part Two of Phase 2B Dose-Ranging, Efficacy Study for ATB-346

Business Wire January 21, 2019

Antibe Therapeutics Raises $1.6 Million Through Warrant Exercises

Business Wire December 19, 2018

Antibe Therapeutics to Present at the 11th Annual LD Micro Main Event on December 4, 2018

Business Wire November 30, 2018

Antibe Therapeutics Announces Successful Completion of Part One of Phase 2B Dose-Ranging, Efficacy Study for ATB-346

Business Wire November 27, 2018

Antibe Therapeutics Reports Q2 2019 Interim Financial and Operating Results

Business Wire November 23, 2018

Antibe Therapeutics Establishes Business Development Advisory Board

Business Wire October 22, 2018

Antibe Therapeutics Receives Approval to Initiate Part One of Phase 2B Dose-Ranging, Efficacy Study for ATB-346

Business Wire October 10, 2018

Antibe Therapeutics Announces Grant of Restricted Share Units

Business Wire October 3, 2018

Antibe Therapeutics Announces Strategic Licensing Deal for Lead Drug in South Korea

Business Wire September 5, 2018

Antibe Therapeutics Reports Q1 2019 Interim Financial and Operating Results

Business Wire August 29, 2018

Antibe Provides Scientific Report on Its Recently Completed Phase 2B Study Showing Unequivocal Gastrointestinal Safety of ATB-346

Business Wire August 29, 2018